Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
111 results about "Vitamin D Compound" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vitamin D Varieties. Vitamin D is a naturally occurring chemical compound, also known as calcitriol. The term "vitamin D" itself can refer to several types of related steroid molecules, such as vitamin D-3, or cholecalciferol, and vitamin D-2, or ergosterol.
Functional vitamin D derivatives and a method for determining 25-hydroxy-vitamin D and 1alpha, dihydroxy-vitamin D
Vitamin D compounds of formula (I) with a label attached to a spacer group in the 3 position are disclosed.In the above formula (I), X is an optionally substituted hydrocarbon group with a length of 0.8-4.2 nm, optionally containing the heteroatoms S, O, N or P; Y is H or OH; A is a label capable of binding with high affinity to a protein; R is an optionally substituted hydrocarbon side chain of a D vitamin or a D vitamin metabolite. Also disclosed is the preparation of formula (I).
Owner:IMMUNDIAGNOSTIK +1
Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
InactiveUS20050101576A1Minimizing and avoiding effectUseful in treatmentOrganic active ingredientsBiocideActive agentHigh doses
Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Other methods include intermittent administration of a high dose of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Such intermittent administration allows high doses of the vitamin D compounds to be administered while minimizing or eliminating hypercalcemia.
Owner:NOVACEA INC
Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
InactiveUS20080312198A1Maximum safetyGood effectOrganic active ingredientsBiocideMedicineProgesterone agent
The present invention relates to pharmaceutical products containing progestins in combination with the 25 hydroxy Vitamin D compounds. The 25 hydroxy Vitamin D compounds are preferably administered with the progestins. In OC and HRT regimens, the 25 hydroxy Vitamin D compounds can be administered daily, or on a non-daily basis, and if so, preferably when the progestin dosages are the highest in the cycle.
Owner:RODRIGUEZ GUSTAVO C
Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
InactiveUS20080312197A1Maximum safetyGood effectBiocideOrganic active ingredientsMedicineVitamin D+Metabolites
The present invention relates to pharmaceutical products containing progestins in combination with the 25 hydroxy Vitamin D compounds. The 25 hydroxy Vitamin D compounds are preferably administered with the progestins. In OC and HRT regimens, the 25 hydroxy Vitamin D compounds can be administered daily, or on a non-daily basis, and if so, preferably when the progestin dosages are the highest in the cycle.
Owner:RODRIGUEZ GUSTAVO C
Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
InactiveUS20070027120A1Fast concentrationQuick eliminationOrganic active ingredientsBiocideActive agentHigh doses
Owner:WHITEHOUSE MARTHA J +1
Pharmaceutical compositions comprising active vitamin D compounds
Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase component.
Owner:CHEN ANDREW X +3
Targeted therapeutic delivery of vitamin D compounds
InactiveUS6929797B2Reduce riskOrganic active ingredientsBiocideTreatment effectMolecular Targeted Therapies
The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need thereof. When a particularly preferred form is administered to a patient, the targeting molecule component of the conjugate of this invention seeks out and binds to a tissue of interest, such as bone or tumor tissue, where the vitamin D has a therapeutic effect.
Owner:BONE CARE INT
Methods for reducing body fat using vitamin D compounds
InactiveUS20050143358A1Reducing total body fatReduce componentsBiocideOrganic active ingredientsCompound (substance)Overweight
A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D3, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.
Owner:WISCONSIN ALUMNI RES FOUND
Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
The preparation of vitamin D compounds of formula (I) with a label attached to a spacer group in the 3 position is disclosed.In the above formula (I), O represents the oxygen atom of an ether group; Y represents hydrogen or hydroxy; A represents a label such as biotin, digoxigenin, or another vitamin D group; R represents a substituted hydrocarbon side-group of vitamin D or a vitamin D metabolite. Also disclosed is a method of measuring 25-hydroxy vitamin D metabolite and a 1α,25-dihydroxy vitamin D metabolite in a sample.
Owner:IMMUNDIAGNOSTIK AG +1
Methods for reducing body fat using vitamin D compounds
InactiveUS7053075B2Reducing total body fatReduce componentsBiocideOrganic active ingredientsOverweightCvd risk
A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D3, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.
Owner:WISCONSIN ALUMNI RES FOUND
Functional vitamin D derivatives and method of determining 25-hydroxy- and 1alpha, 25-dihydroxy vitamin D
InactiveUS20050014211A1High yieldShort reaction timePeptide preparation methodsDepsipeptidesHydrogenEther
The preparation of vitamin D compounds of formula (I) with a label attached to a spacer group in the 3 position is disclosed. In the above formula (I), O represents the oxygen atom of an ether group; Y represents hydrogen or hydroxy; A represents a label such as biotin, digoxigenin, or another vitamin D group; R represents a substitured hydrocarbon side-group of vitamin D or a vitamin D metabolite. Also disclosed is a method of measuring 25-hydroxy vitamin D metabolite and a 1α,25-dihydroxy vitamin D metabolite in a sample.
Owner:IMMUNDIAGNOSTIK +1
Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
InactiveUS6858595B2Relieve symptomsAvoid symptomsOrganic active ingredientsBiocideInflammatory bowel diseaseActive Vitamin D
Methods of treating inflammatory bowel disease are described, and in particular the prevention and treatment of inflammatory bowel disease in humans as well as other animals. These methods involve the administration of biologically active vitamin D compounds, and therapeutic compositions thereof, so that the symptoms of Inflammatory Bowel Disease are reduced or relieved.
Owner:WISCONSIN ALUMNI RES FOUND
Pharmaceutical compositions comprising active vitamin D compounds
InactiveUS20060189586A1Shorter TmaxOvercome disadvantagesBiocideOrganic active ingredientsEmulsionActive Vitamin D
Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase component.
Owner:NOVACEA INC
Oral controlled release compositions comprising vitamin d compound and waxy carrier
Owner:OPKO IP HLDG II INC +1
Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
InactiveUS20070275934A1Reduced hypercalcemic effectIncrease doseBiocideOrganic active ingredientsHigh dosesActive Vitamin D
The present invention relates to a method for treating or ameliorating pancreatic cancer in an animal by administering to the animal active vitamin D compounds by high dose pulse administration in combination with one or more chemotherapeutic agents or radiotherapeutic agents / treatments.
Owner:CURD JOHN G
Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds
InactiveUS20080194528A1Overcome disadvantagesSustained stabilityOrganic active ingredientsBiocideDiseaseElastomer
Owner:GALDERMA RES & DEV SNC
Treatment fo systemic lupus erythematosis
InactiveUS20020028830A1Diminishes SLE symptomRelieve symptomsBiocideMetabolism disorderVitamin D CompoundSystemic lupus
A method of treating SLE symptoms of an SLE patient comprising administering to an SLE patient an amount of vitamin D compound effective to reduce symptoms and observing a reduction in symptoms is disclosed.
Owner:WISCONSIN ALUMNI RES FOUND
Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
InactiveUS20050080059A1Prevent and treat IBDPreventing inflammatory bowel diseaseOrganic active ingredientsBiocideCrohn's diseaseUlcerative colitis
A method of preventing and / or treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a 2-methylene-19-nor-vitamin D compound in an amount effective to treat the disease. The administration of a 2-methylene-19-nor-vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals. The preferred compounds are 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3.
Owner:PENN STATE RES FOUND +1
Method of extending the dose range of vitamin D compounds
InactiveUS7259143B2Inhibiting hypercalcemiaMinimal dangerBiocideOrganic active ingredientsDiseaseCalcification
Inhibitors of bone calcium resorption are administered to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating non-calcium related diseases such as cancer, psoriasis, and autoimmune disease without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-κB ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-κB gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1α,25-dihydroxyvitamin D3 (1,25-(OH)2D3), its analogs, prodrugs, or mimetics can be utilized with minimal risk to a patient. Specifically, alendronate is shown to block the bone calcium mobilization activity of both 1,25-(OH)2D3 and its very potent analog, 2-methylene -19-nor-(20S)-1α,25-dihydroxyvitamin D3.
Owner:WISCONSIN ALUMNI RES FOUND
Release reagent for vitamin d compounds
The present invention concerns a reagent composition for releasing vitamin D compounds bound to vitamin D-binding protein, a method for the detection of a 25-hydroxyvitamin D compound in which the 25-hydroxyvitamin D compound is released from vitamin D-binding protein using this reagent and the mixture obtained in this manner is analyzed, the use of the reagent to release vitamin D compounds as well as a kit for detecting 25-hydroxyvitamin D which contains the reagent for releasing vitamin D compounds in addition to the usual immunological reagents.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Compositions Comprising Strontium and Vitamin D and Uses Thereof
InactiveUS20080026037A1Convenient treatmentFew side-effectsHeavy metal active ingredientsBiocideStrontium carbonateStrontium chloride
The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment and prevention of bone disorders such as osteoporosis. The composition preferably comprises strontium carbonate and strontium chlorides. Further included may be a vitamin D compound, preferably vitamin D3.
Owner:MOKWALO SPF SA
Immunoassay for free vitamin d
ActiveUS20130143241A1Preparing sample for investigationBiological testingSolubilityCompetitive binding
Disclosed is the invention to conduct immuno-adsorption of free 25(OH) vitamin D from blood or blood components, notably serum or plasma, after which the absorbed material is measured. A fluoro-alkyl surfactant is used to enhance the solubility of Vitamin D and allow the measurement of free Vitamin D. The invention thus employs a binding protein to absorb the free 25(OH) vitamin D. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound, preferably radiolabeled, fluorescent labeled, luminescent labeled, biotin labeled, gold labeled or enzyme labeled. Alternatively the immunocaptured 25-OH vitamin D can be quantitated by mass spectrometry.
Owner:FUTURE DIAGNOSTICS
Vitamin d3 and analogs thereof for treating alopecia
The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication.
Owner:BPGBIO INC
Petroleum jelly-free unguent compositions comprising vitamin D compounds and optionally steroidal anti-inflammatory agents
InactiveUS20090298801A1No reduction in viscosityEasy to prepareOrganic active ingredientsBiocideWhite petrolatumMedicine
Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.
Owner:GALDERMA SA
Treatment of systemic lupus erythematosis
InactiveUS6673782B2Diminishes SLE symptomAvoid developmentBiocideMetabolism disorderVitamin D CompoundSystemic lupus
Owner:WISCONSIN ALUMNI RES FOUND
Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
InactiveUS20020128241A1Relieve symptomsAvoid symptomsOrganic active ingredientsBiocideInflammatory bowel diseaseActive Vitamin D
Methods of treating inflammatory bowel disease are described, and in particular the prevention and treatment of inflammatory bowel disease in humans as well as other animals. These methods involve the administration of biologically active vitamin D compounds, and therapeutic compositions thereof, so that the symptoms of Inflammatory Bowel Disease are reduced or relieved.
Owner:WISCONSIN ALUMNI RES FOUND
Release reagent for vitamin d
Disclosed is an invention in the field of conducting an immunoassay of 25(OH) vitamin D in blood or blood components, notably serum or plasma. The invention employs a perfluoro alkyl acid, or a salt thereof, to release 25(OH) vitamin D from vitamin D binding protein. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound.
Owner:FUTURE DIAGNOSTICS
Method of locking 1alpha-OH of vitamin D compounds in axial orientation
InactiveUS6890914B2Improve biological activityOrganic active ingredientsBiocideChemistryVitamin D Compound
A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1α-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1α-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1α-hydroxyl in the axial orientation.
Owner:WISCONSIN ALUMNI RES FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com